In addition, the mutational burden of EBV-positive DLBCL has been found to be lower than that of EBV-negative DLBCL, and the presence of EBV may substitute for mutations in driver genes, such as MYD88 and CD79A [97]. The gene discussed is CD79A; the disease is diffuse large B-cell lymphoma.